Physician profile
Michael L Cogan
NPI 1609889815
$2,590.39
in general payments reported to CMS, 2019-2025
23 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $231 · 2021: $327 · 2022: $356 · 2023: $279 · 2024: $189 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.64 | 2019-2023 | Lo Loestrin Fe |
| Organon LLC | $277.06 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $177.70 | 2025 | Gemtesa, Myfembree |
| Allergan, INC. | $170.34 | 2019-2020 | |
| Roche Diagnostics Corporation | $99.13 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $89.96 | 2019 | |
| Sage Therapeutics, LLC | $81.44 | 2019-2024 | |
| Intuitive Surgical, INC. | $79.88 | 2019 | |
| Mayne Pharma Commercial LLC | $79.58 | 2023-2025 | |
| Aspira Women'S Health INC | $75.37 | 2019-2024 | Ova1 |
| Shield Therapeutics INC | $68.08 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $59.64 | 2020-2022 | |
| Hologic Sales and Service, LLC | $52.75 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Minerva Surgical, INC | $29.78 | 2023 | |
| Baxter Healthcare | $28.26 | 2024 | Perclot |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.45 | 2025 | |
| Merck Sharp & Dohme LLC | $25.92 | 2021 | |
| Agile Therapeutics, INC. | $23.33 | 2023 | Twirla |
| Horizon Therapeutics Plc | $19.96 | 2021 | |
| Myovant Sciences INC. | $19.01 | 2022 | |
| Exeltis, USA INC. | $18.86 | 2022 | |
| Therapeuticsmd, INC. | $17.73 | 2022 | |
| Evofem Biosciences, INC. | $15.52 | 2023 | Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.